Erratum to: The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia(Br J Haematol., (2008), 142, (5), (775–85), 10.1111/j.1365-2141.2008.07257.x);The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia

British Journal of Haematology

Volumn 142, Issue 5, 2008, Pages 775-785

  Moreau, Anne Sophie ^a,b   Jia, Xiaoying ^a   Patterson, Christopher J ^a   Roccaro, Aldo M ^a   Xu, Lian ^a   Sacco, Antonio ^a   O'Connor, Kelly ^a   Soumerai, Jacob ^a   Ngo, Hai T ^a   Hatjiharissi, Evdoxia ^a   Hunter, Zachary R ^a   Ciccarelli, Bryan ^a   Manning, Robert ^a   Ghobrial, Irene M ^a   Leleu, Xavier ^a,b   Treon, Steven P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

HMG CoA reductase inhibitor; Simvastatin; Waldenstrom macroglobulinemia

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; FLUDARABINE; GERANYLGERANYL PYROPHOSPHATE; IMMUNOGLOBULIN M; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SIMVASTATIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG INHIBITION; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; IN VITRO STUDY; PRIORITY JOURNAL; WALDENSTROEM MACROGLOBULINEMIA;

EID: 48749132534     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.19479     Document Type: Erratum

References (33)

1. Ahn, K.S., Sethi, G. Aggarwal, B.B. (2007) Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. Journal of Immunology, 178, 2507 2516.
2. Al-Katib, A.M., Mensah-Osman, E., Aboukameel, A. Mohammad, R. (2003) The Wayne State University Waldenstrom's macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia. Seminars in Oncology, 30, 313 317.
3. Chen, C.I., Kouroukis, C.T., White, D., Voralia, M., Stadtmauer, E., Stewart, A.K., Wright, J.J., Powers, J., Walsh, W. Eisenhauer, E. (2007) Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 25, 1570 1575.
4. Chng, W.J., Schop, R.F., Price-Troska, T., Ghobrial, I., Kay, N., Jelinek, D.F., Gertz, M.A., Dispenzieri, A., Lacy, M., Kyle, R.A., Greipp, P.R., Tschumper, R.C., Fonseca, R. Bergsagel, P.L. (2006) Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood, 108, 2755 2763.
5. Denoyelle, C., Albanese, P., Uzan, G., Hong, L., Vannier, J.P., Soria, J. Soria, C. (2003) Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cellular Signalling, 15, 327 338.
6. Detter, J.C., Zhang, Q., Mules, E.H., Novak, E.K., Mishra, V.S., Li, W., McMurtrie, E.B., Tchernev, V.T., Wallace, M.R., Seabra, M.C., Swank, R.T. Kingsmore, S.F. (2000) Rab geranylgeranyl transferase alpha mutation in the gunmetal mouse reduces Rab prenylation and platelet synthesis. Proceedings of the National Academy of Sciences of the United States of America, 97, 4144 4149.
7. van de Donk, N.W., Kamphuis, M.M., Lokhorst, H.M. Bloem, A.C. (2002) The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia, 16, 1362 1371.
8. van de Donk, N.W., Schotte, D., Kamphuis, M.M., van Marion, A.M., van Kessel, B., Bloem, A.C. Lokhorst, H.M. (2003) Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells. Clinical Cancer Research, 9, 5735 5748.
9. van de Donk, N.W., Lokhorst, H.M., Nijhuis, E.H., Kamphuis, M.M. Bloem, A.C. (2005) Geranylgeranylated proteins are involved in the regulation of myeloma cell growth. Clinical Cancer Research, 11, 429 439.
10. Elsawa, S.F., Novak, A.J., Grote, D.M., Ziesmer, S.C., Witzig, T.E., Kyle, R.A., Dillon, S.R., Harder, B., Gross, J.A. Ansell, S.M. (2006) B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood, 107, 2882 2888.
11. Frost, J.A., Steen, H., Shapiro, P., Lewis, T., Ahn, N., Shaw, P.E. Cobb, M.H. (1997) Cross-cascade activation of ERKs and ternary complex factors by Rho family proteins. EMBO Journal, 16, 6426 6438.
12. Hatzimichael, E.C., Christou, L., Bai, M., Kolios, G., Kefala, L. Bourantas, K.L. (2001) Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenstrom's macroglobulinemia. European Journal of Haematology, 66, 1 6.
13. Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F.E., Tai, Y.T., Treon, S.P., Lin, B., Schlossman, R.L., Richardson, P., Muller, G., Stirling, D.I. Anderson, K.C. (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96, 2943 2950.
14. Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., Adams, J. Anderson, K.C. (2002) NF-kappa B as a therapeutic target in multiple myeloma. Journal of Biological Chemistry, 277, 16639 16647.
15. Hideshima, T., Catley, L., Yasui, H., Ishitsuka, K., Raje, N., Mitsiades, C., Podar, K., Munshi, N.C., Chauhan, D., Richardson, P.G. Anderson, K.C. (2006) Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood, 107, 4053 4062.
16. Kozar, K., Kaminski, R., Legat, M., Kopec, M., Nowis, D., Skierski, J.S., Koronkiewicz, M., Jakobisiak, M. Golab, J. (2004) Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. International Journal of Oncology, 24, 1149 1157.
17. Liang, S.L., Liu, H. Zhou, A. (2006) Lovastatin-induced apoptosis in macrophages through the Rac1/Cdc42/JNK pathway. Journal of Immunology, 177, 651 656.
18. Lundberg, A.S. Weinberg, R.A. (1998) Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Molecular and Cellular Biology, 18, 753 761.
19. Moreau, A.S., Jia, X., Ngo, H.T., Leleu, X., O'Sullivan, G., Alsayed, Y., Leontovich, A., Podar, K., Kutok, J., Daley, J., Lazo-Kallanian, S., Hatjiharissi, E., Raab, M.S., Xu, L., Treon, S.P., Hideshima, T., Anderson, K.C. Ghobrial, I.M. (2007) Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood, 109, 4964 4972.
20. Moyad, M.A., Merrick, G.S., Butler, W.M., Wallner, K.E., Galbreath, R.W., Kurko, B. Adamovich, E. (2005) Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology, 66, 1150 1154.
21. Okkenhaug, K. Vanhaesebroeck, B. (2003) PI3K in lymphocyte development, differentiation and activation. Nature Reviews. Immunology, 3, 317 330.
22. Owen, R.G., Treon, S.P., Al-Katib, A., Fonseca, R., Greipp, P.R., McMaster, M.L., Morra, E., Pangalis, G.A., San Miguel, J.F., Branagan, A.R. Dimopoulos, M.A. (2003) Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia. Seminars in Oncology, 30, 110 115.
23. Patterson, C.J. (2006) Abnormalities in lipoprotein metabolism provide insight into novel therapeutic approaches for Waldenstrom's macroglobulinemia. Blood, (ASH Annual Meeting Abstracts), 108, 270b, abstract 4749.
24. Poon, R.Y., Jiang, W., Toyoshima, H. Hunter, T. (1996) Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage. Journal of Biological Chemistry, 271, 13283 13291.
25. Roudier, E., Mistafa, O. Stenius, U. (2006) Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Molecular Cancer Therapeutics, 5, 2706 2715.
26. Santos, D.D., Hatjiharissi, E., Tournilhac, O., Chemaly, M.Z., Leleu, X., Xu, L., Patterson, C., Branagan, A.R., Manning, R.J., Ho, A.W., Hunter, Z.R., Dimmock, E.A., Kutok, J.L., Churchill, W.H., Castells, M.C., Tai, Y.T., Anderson, K.C. Treon, S.P. (2006) CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's macroglobulinemia and mast cell disorders. Clinical Lymphoma and Myeloma, 6, 478 483.
27. Seabra, M.C. (1998) Membrane association and targeting of prenylated Ras-like GTPases. Cellular Signalling, 10, 167 172.
28. van der Spek, E., Bloem, A.C., van de Donk, N.W., Bogers, L.H., van der Griend, R., Kramer, M.H., de Weerdt, O., Wittebol, S. Lokhorst, H.M. (2006) Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica, 91, 542 545.
29. Tassone, P., Neri, P., Kutok, J.L., Tournilhac, O., Santos, D.D., Hatjiharissi, E., Munshi, V., Venuta, S., Anderson, K.C., Treon, S.P. Munshi, N.C. (2005) A SCID-hu in vivo model of human Waldenstrom macroglobulinemia. Blood, 106, 1341 1345.
30. Thibault, A., Samid, D., Tompkins, A.C., Figg, W.D., Cooper, M.R., Hohl, R.J., Trepel, J., Liang, B., Patronas, N., Venzon, D.J., Reed, E. Myers, C.E. (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clinical Cancer Research, 2, 483 491.
31. Tobert, J.A. (2003) Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature Reviews. Drug Discovery, 2, 517 526.
32. Treon, S.P., Gertz, M.A., Dimopoulos, M., Anagnostopoulos, A., Blade, J., Branagan, A.R., Garcia-Sanz, R., Johnson, S., Kimby, E., Leblond, V., Fermand, J.P., Maloney, D.G., Merlini, G., Morel, P., Morra, E., Nichols, G., Ocio, E.M., Owen, R. Stone, M.J. (2006) Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood, 107, 3442 3446.
33. Vijay, A. Gertz, M.A. (2007) Waldenstrom macroglobulinemia. Blood, 109, 5096 5103.